Thoueille et al., Restkonzentrationen und Wirksamkeit von lang wirkendem Cabotegravir und Rilpivirin im realen Leben
Restkonzentrationen und Wirksamkeit von lang wirkendem Cabotegravir und Rilpivirin im realen Leben: eine prospektive, multizentrische Beobachtungsstudie in der Schweiz.   The Lancet Regional Health – Europe Die Behandlung von HIV hat in den letzten Jahren große Fortschritte gemacht. Es wurden neue Medikamente wie lang wirkendes Cabotegravir und Rilpivirin eingeführt, die in Form von Injektionen in regelmäßigen Abständen […]
Chammartin et al., Factors impacting mRNA Sars-CoV-2 vaccine booster response in PWH
Bridging the gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1.   AIDS Chammartin et al. aimed at investigating which factors substantially impact vaccine immunogenicity after a third mRNA vaccination in people with HIV (PWH). Serological measurements were conducted on a total of 439 PWH who had received a third dose of […]
Berton et al., Exposure and response of antiretrovirals in obese PWH
Antiretroviral drug exposure and response in obese and morbidly obese people with human immunodeficiency virus (HIV): A study combining modelling and Swiss HIV Cohort Data Clinical Infectious Diseases Several physiological changes impact drug exposure in individuals with obesity. Increased liver blood flow or higher glomerular filtration rate can accelerate metabolic clearance, and drugs accumulated in the […]
Abela et al., Gender disparities in statin prescriptions in people with HIV
Gender disparities in statin prescriptions in people with HIV with low/moderate to high cardiovascular risk.  Open Forum Infectious Diseases Abela et al. aimed to explore whether gender and ethnicity influence statin prescriptions for cardiovascular disease (CVD) prevention in people with HIV in Switzerland, a high-income country with a high standard of care and more equitable access compared […]
Griessbach et al., Réponses des anticorps après la troisième vaccination avec le vaccin Moderna ou BioNTech de Pfizer
Réponses des anticorps après la troisième vaccination avec le vaccin Moderna ou le vaccin BioNTech de Pfizer chez des personnes présentant différentes immunosuppressions.   Open Forum Infectious Diseases L’étude COVERALL (COronaVaccinE tRiAL pLatform) est intégrée à l’Etude suisse de cohorte VIH (SHCS) et à la cohorte suisse de transplantation (STCS). Dans la première étude COVERALL, les […]
Griessbach et al., Risposta immunitaria dopo la terza vaccinazione con il vaccino Moderna o BioNTech di Pfizer
Risposta immunitaria dopo la terza vaccinazione con il vaccino Moderna o BioNTech di Pfizer in persone con diverse forme di immunosoppressione. Open Forum Infectious Diseases Lo studio COVERALL (COronaVaccinE tRiAL pLatform) si è svolto nel contesto dello Swiss HIV Cohort Study (SHCS) e dello Swiss Transplant Cohort Study (STCS). Nel primo studio COVERALL, il vaccino Moderna […]
Griessbach et al., Antikörperantworten nach der dritten Impfung mit dem Moderna- oder dem Pfizer-BioNTech-Impfstoff
Antikörperantworten nach der dritten Impfung mit dem Moderna-Impfstoff oder dem Pfizer-BioNTech-Impfstoff bei Personen mit unterschiedlicher Immunsuppression. Open Forum Infectious Diseases Die COVERALL (COrona VaccinE tRiAL pLatform)-Studie ist in die Schweizerische HIV-Kohortenstudie (SHCS) und Schweizerische Transplantationskohorte (STCS) eingebettet. In der ersten COVERALL-Studie wurde der Moderna-Impfstoff mRNA-1273 mit dem Pfizer-BioNTech-Impfstoff BNT162b2 hinsichtlich der Antikörperantwort nach der Grundimmunisierung mit […]
Begré et al., HIV/HBV coinfection and HBsAg loss during tenofovir therapy
Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.   The Journal of Infectious Diseases Novel hepatitis B virus (HBV) serum markers have improved our understanding of the HBV replication cycle. Among these markers, hepatitis B core-related antigen (HBcrAg) serves as a surrogate for measuring the […]
Zeeb et al., Genetic diversity from proviral DNA as a proxy for time since HIV-1 infection
Genetic diversity from proviral DNA as a proxy for time since HIV-1 infection.  Journal of Infectious Diseases HIV-1 RNA genetic diversity predicts time since infection, which is important for clinical care and research. It is unclear, however, whether proviral DNA genetic diversity sampled under suppressive antiretroviral therapy can be used for this purpose. In this study, […]
Trickey et al., Mortality in spectrum among adults with HIV
Estimation of improvements in mortality in spectrum among adults with HIV receiving antiretroviral therapy in high-income countries.   JAIDS Trickey et al. aimed to review AIDS-related and non–AIDS related mortality rates over time using data from a collaboration of cohorts of people living with HIV (PLHIV) on antiretroviral therapy (ART) in Europe and compare the estimated mortality rates […]